Emerging Therapeutic Approaches of SHP2-Targeted Modulators

Tweetable abstract

Monotherapy and combination therapy of SHP2 regulator for cancer treatment.

Keywords::

• combination therapy
• epigenetic inhibitors
• immune checkpoint blockers
• kinase inhibitors
• protein tyrosine phosphatases
• SHP2 modulator

Financial disclosure

This work is supported by the Natural Science Foundation of China (Nos. 32371317, 22277110 and 82104279), ‘Chunhui Plan’ Cooperative Scientific Research Project of the Ministry of Education (No. HZKY20220280), Natural Science Foundation of Henan Province (Nos. 222300420069 and 222301420049). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work is supported by the Natural Science Foundation of China (Nos. 32371317, 22277110 and 82104279), ‘Chunhui Plan’ Cooperative Scientific Research Project of the Ministry of Education (No. HZKY20220280), Natural Science Foundation of Henan Province (Nos. 222300420069 and 222301420049). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.